Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups

Author:

Colombo Cinzia1,Caldara Daniele2,Banzi Rita3

Affiliation:

1. Laboratory of Medical Research on Consumer Involvement, Department of Medical Epidemiology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy

2. Altroconsumo—Independent Consumer Organization Health Department Milan Italy

3. Center for Health Regulatory Policies Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy

Abstract

AbstractIntroductionAccess to medicines is one of the biggest challenges to health systems, affecting society and individuals. This study aims to explore citizens' opinions, perceptions and attitudes on the model of medicines' research and development (R&D) and price setting of medicines reimbursed by the Italian National Health Service.Materials and MethodsWe run four online focus groups, analysed through thematic analysis. Inclusion criteria: people aged 30–70 years, who had completed at least compulsory schooling (8–10 years), with no specialised knowledge about the subject. Exclusion criteria: healthcare workers, pharmaceutical and device industry employees, researchers and medicine policy board members. We aimed to include a purposive sample of 20 participants, variable in terms of age, educational level and place of residence.ResultsEleven women and six men participated. The mean age was 53 years (range: 28–73). Most (n = 15) had a university degree or attended secondary schools. Eight had a job, five were not employed, and four were retired. In general, participants supported the role of the public health service. Almost all had limited knowledge of medicines' R&D and price setting. Most asked for transparency on medicine prices and negotiation criteria. Participants considered revenues of pharmaceutical companies disproportionate and most called for containment measures of profits. Most were in favour of a stronger public intervention in R&D and prices' negotiations. Few were sceptical of the public sector's ability to play this role.DiscussionMedicines' prices were discussed as a health matter. Increasing citizens' awareness of these topics is needed by providing spaces and conditions to participate in the discussion, including different perspectives and interests.Patient or Public ContributionMembers of BEUC—the European consumer organisation—proposed the project. Altroconsumo, an independent consumer organisation and OCU, a Spanish consumer organisation, participated in developing the project and the main topics to discuss. The Mario Negri Institute and Aplica cooperative—the Spanish methodological team—were involved by BEUC and their national organisations to define the methodology, organisational aspects and contents and conducted the focus groups.

Publisher

Wiley

Reference40 articles.

1. IQVIA Institute. The Global Use of Medicine in 2019 and Outlook to 2023. January2019. Accessed October 11 2023.https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023

2. USA grapples with high drug costs

3. Inflation Reduction Act and US drug pricing

4. Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3